Small cell lung cancer (SCLC) is the most aggressive lung cancer subtype and little progress has been made in understanding the molecular mechanisms causing this devastating disease. No mechanistic explanation exists for a central clinical hallmark: While SCLC typically presents with initial sensitivity against chemotherapy, the disease almost inevitably relapses. Recent discoveries in SCLC genomics and transcriptomics have now provided first mechanistic insight into the biology of this deadly disease. 

Latest Publications

  • NEMO- and RelA-dependent NF-κB signaling promotes small cell lung cancer
    Koerner L, Schmiel M, Yang TP, Peifer M, Buettner R, Pasparakis M. Cell Death Differ. 2023 Jan 18. doi: 10.1038/s41418-023-01112-5. Epub ahead of print.
    PMID: 36653597
  • Staining of activated ß2-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells.
    Schöllhorn A, Maia A, Kimmerle F, Born J, Rammensee H-G, Dimitrov S and Gouttefangeas C. Front. Immunol. 2023 Jan. 13:1107366. doi: 10.3389/fimmu.2022.1107366
  • Integrin activation enables rapid detection of functional Vδ1+ and Vδ2+ γδ T cells
    Herold N, Schöllhorn A, Feile A, Gaißler A, Mohrholz A, Pawelec G, Löffler MW, Dimitrov S, Gouttefangeas C, Wistuba-Hamprecht K. Eur J Immunol. 2022 May;52(5):730-736. doi: 10.1002/eji.202149682. Epub 2022 Feb 21.
    PMID: 35133647
  • CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization
    Werr L, Plenker D, Dammert M A., Lorenz C, Brägelmann J, Tumbrink H L., Klein S, Schmitt A, Büttner R, Persigehl T, Shokat K M., Wunderlich T, Schram A M., Peifer M, Sos M L, Reinhardt H C., Thomas R K.
    Mol Cancer Ther. 2022 Feb
    PMID: 35247925